HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
Jul
30
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL
Jul
04
VOLUNTARY ANNOUNCEMENT - MESALAZINE ENTERIC-COATED TABLETS OBTAIN DRUG REGISTRATION APPROVAL
Jul
03
VOLUNTARY ANNOUNCEMENT - HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA (MMA)
Jun
27
NOMINATION COMMITTEE - TERMS OF REFERENCE
Jun
27
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Jun
27
CHANGE IN COMPOSITION OF NOMINATION COMMITTEE
Jun
24
CONNECTED TRANSACTIONS - LEASE AGREEMENTS
Jun
23
VOLUNTARY ANNOUNCEMENT - MELOXICAM INJECTION (III) OBTAINS DRUG REGISTRATION APPROVAL
Jun
13
VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA
Jun
10
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun
05
VOLUNTARY ANNOUNCEMENT - COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Jun
02
VOLUNTARY ANNOUNCEMENT - JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER
May
30
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 30 MAY 2025
May
30
VOLUNTARY ANNOUNCEMENT - POTENTIAL LICENSE AND COLLABORATION
May
29
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2025
May
19
VOLUNTARY ANNOUNCEMENT - CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC
May
19
VOLUNTARY ANNOUNCEMENT - JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
May
19
DATE OF BOARD MEETING
May
15
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION
May
12
VOLUNTARY ANNOUNCEMENT - VONOPRAZAN FUMARATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
May
09
VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
May
02
VOLUNTARY ANNOUNCEMENT - JMT202 (RECOMBINANT FULLY HUMAN ANTI-BETA KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
30
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS
Apr
28
NOTICE OF ANNUAL GENERAL MEETING
Apr
25
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Apr
23
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025
Apr
22
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
15
VOLUNTARY ANNOUNCEMENT - OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL
Apr
14
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Apr
11
VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Apr
08
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
28
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
28
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024
Mar
21
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Mar
20
FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024
Mar
18
DATE OF BOARD MEETING
Mar
18
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Mar
13
VOLUNTARY ANNOUNCEMENT - SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Mar
05
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Feb
28
VOLUNTARY ANNOUNCEMENT - SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA
Feb
25
PROFIT WARNING
Feb
19
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA
Feb
10
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR ENYITAN (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL
Feb
10
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Feb
07
VOLUNTARY ANNOUNCEMENT - SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Feb
06
CHANGE OF SHARE REGISTRAR
Jan
20
VOLUNTARY ANNOUNCEMENT - REGORAFENIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL
Jan
17
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024
Jan
16
VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jan
13
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN TABLETS OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Jan
10
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Jan
07
VOLUNTARY ANNOUNCEMENT - SYS6045 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL
Jan
07
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL
Jan
02
VOLUNTARY ANNOUNCEMENT - SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer